Krishnan Suma sold $7.7M of KRYS
Krishnan Suma (President, R&D) sold 25,000 shares of Krystal Biotech, Inc. (KRYS) at an average of $308.11 ($300.75–$311.65, $7.70M total) across 11 trades on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale provides fresh data on insider sentiment, which traders may use to adjust positions.
Market read
First‑report insider sale of $7.7M; modest but material for a micro‑cap biotech.
What to watch
Upcoming clinical trial data or partnership announcements could offset sell‑off concerns.
Background
SEC Form 4 filing discloses an insider transaction for Krystal Biotech, Inc.
Ticker impact
President of R&D sold 25,000 shares for $7.7M via a 10b5-1 plan, reducing his stake to 1.38M shares.
potential downward pressure as market absorbs the $7.7M insider sale
The sale is sizable for a micro‑cap biotech and executed through a pre‑arranged plan, suggesting possible future dilution or lack of confidence.
Market effects
May raise caution for other small‑cap biotech stocks as insider activity is monitored.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact; only relevant to KRYS shareholders.
Counterpoint
The sale could be purely liquidity‑driven under a 10b5‑1 plan, not a bearish signal.
Key entities
- OfficerKrishnan Suma
President, R&D and 10% owner of Krystal Biotech
- CompanyKrystal Biotech, Inc.
Biotech firm listed on NASDAQ under ticker KRYS
